Alpine Immune Sciences Inc (NASDAQ:ALPN) – Equities research analysts at Piper Jaffray Companies dropped their FY2018 earnings per share (EPS) estimates for shares of Alpine Immune Sciences in a research report issued on Sunday, November 11th. Piper Jaffray Companies analyst E. Tenthoff now forecasts that the biotechnology company will post earnings per share of ($2.44) for the year, down from their prior estimate of ($2.17). Piper Jaffray Companies has a “Overweight” rating and a $12.00 price target on the stock. Piper Jaffray Companies also issued estimates for Alpine Immune Sciences’ Q4 2018 earnings at ($0.61) EPS, Q1 2019 earnings at ($0.60) EPS, Q2 2019 earnings at ($0.66) EPS, Q3 2019 earnings at ($0.65) EPS, Q4 2019 earnings at ($0.71) EPS and FY2019 earnings at ($2.63) EPS.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.31). Alpine Immune Sciences had a negative return on equity of 43.25% and a negative net margin of 1,602.19%.

Other research analysts have also issued research reports about the company. Oppenheimer set a $13.00 price objective on Alpine Immune Sciences and gave the company a “buy” rating in a research report on Monday. Raymond James initiated coverage on Alpine Immune Sciences in a research report on Monday, August 13th. They set a “buy” rating and a $13.00 price objective for the company. Zacks Investment Research upgraded Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 25th. Finally, ValuEngine upgraded Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd. Two analysts have rated the stock with a sell rating and five have given a buy rating to the stock. Alpine Immune Sciences presently has a consensus rating of “Hold” and a consensus target price of $12.67.

Shares of Alpine Immune Sciences stock opened at $5.14 on Wednesday. The stock has a market cap of $71.72 million, a PE ratio of -4.28 and a beta of 0.94. The company has a quick ratio of 9.20, a current ratio of 9.20 and a debt-to-equity ratio of 0.05. Alpine Immune Sciences has a twelve month low of $4.61 and a twelve month high of $11.75.

Several institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC grew its position in shares of Alpine Immune Sciences by 20.9% during the second quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock valued at $927,000 after purchasing an additional 21,124 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Alpine Immune Sciences by 122.2% during the second quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 18,052 shares in the last quarter. Finally, DRW Securities LLC grew its position in shares of Alpine Immune Sciences by 138.7% during the second quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 14,143 shares in the last quarter. Hedge funds and other institutional investors own 56.85% of the company’s stock.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Featured Story: Market Capitalization

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.